CluePoints Covid-19 Support Benefits Over 200 Clinical Studies Directly Affected by the Pandemic
Beyond COVID-19: The New Normal in Risk-Based Monitoring (RBM) and Quality Management (RBQM)
EPS Corporation Signs Groundbreaking Agreement To Drive Increased Quality And Safety Using CluePoints RBQM Solution
Early Risk Detection During the COVID-19 Crisis – Your Questions Answered
CluePoints Launches Complimentary COVID-19 Risk Management Package for Clinical Studies
Webinar Recording: The Critical Importance of Early Risk Detection with a Special Feature Addressing COVID-19
Complimentary COVID-19 Risk Assessment Package Available To All at No Cost
CluePoints’ Central Statistical Monitoring Supports Business Continuity as Coronavirus Impacts Clinical Trial Operations
Registration Open for our Risk-Based Quality Management Insights Webinar
Find out where we’re headed next.
ICH E6 (R2)
Created in conjunction with our peers at TUFTS Center for the Study of Drug Development, this paper provides insights on how companies are responding to ICH E6 (R2) and information on the key themes on adoption.
ICH E6 (R2)
This recorded webinar covers all of the frequently asked Questions about ICH E6 (R2), Risk-Based Study Execution (RBx) and what’s required from a people, process & technology standpoint.